PERTH, Australia – Melbourne-based Neuren Pharmaceuticals signed a development and commercialization deal with Acadia Pharmaceuticals Inc. worth up to $465 million for North American rights to trofinetide for Rett syndrome and other indications. Read More
HONG KONG – China's Hangzhou Qihan Bio Inc. has completed a series A financing to raise $7.8 million for the development of xenotransplantation procedures, engineering pig organs to be transplanted into humans. Read More
HONG KONG – South Korea's Samyang Biopharmaceutical Corp. is set to expand to the U.S. with a new office in Boston, scheduled to open this month. The new location will focus on biologics product development as well as leveraging the local network for M&A opportunities. Read More
The high expectations that have been swirling around the nanomedicine field for almost a decade are still yet to be fully realized. However, there are promising signs that significant investments in early stage research over the past few years are starting to reap dividends with new generation therapeutic applications moving into clinical testing. The field is now expanding rapidly, and analysts and industry observers have identified it as a key enabling technology that is likely to impact the development of new therapeutics and diagnostics. Read More
Glenmark Pharmaceuticals SA, of Mumbai, India, and Shanghai-based Harbour Biomed Inc. have entered an exclusive license agreement for the greater China territory to develop, manufacture and commercialize GBR-1302, Glenmark's bispecific antibody targeting HER2 and CD3 for the treatment of HER2-positive cancers. It's Glenmark's lead immuno-oncology candidate. Read More
The finding that subcellular inhibitors of heat shock protein 70 (Hsp70) promote cancer cell death via different mechanisms may lead to novel cancer chemotherapies, by showing the importance of studies of small-molecule subcellular locations and functions in elucidating their detailed mechanisms of action. Read More
